Professor | Jiwu Wei | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Jiwu Wei
Contact Information	nwjw@nju.edu.cn
Language ability	Chinese, German
Province	Jiangsu

Upload Avatar (500 x 500)

Name

Jiwu Wei

Contact Information

nwjw@nju.edu.cn

Language ability

Chinese, German

Province

Jiangsu

University/Lab Affiliation and Title	Nanjing University
Faculty	Medical School
Academic Background & Achievements	1993 - Graduated from Huazhong University of Science and Technology, Clinical Medicine (German class) 2001 - Master's in Pathology from Jinan University Medical School 2003 - PhD from Ulm University Medical School, Germany 2006 - Postdoctoral Researcher at Ulm University Medical School, Germany 2009 - Postdoctoral Researcher at Munich University Medical School, Germany Published research in top journals like Cancer Cell, Cancer Res., Int J Cancer, JVI, Nature Comm., Mol Ther., and BJC Granted 3 invention patents and applied for 10 national invention patents Led 4 national and 2 provincial research projects
Work Experience	1993-2001 - Attending Physician, Neurosurgery, Third Affiliated Hospital of Jinan University Medical School 2001-2003 - PhD Student, Ulm University Medical School, Germany 2003-2006 - Postdoctoral Researcher, Ulm University Medical School, Germany 2007-2009 - Postdoctoral Researcher, Munich University Medical School, Germany 2009-present - Professor and Doctoral Supervisor, Nanjing University Medical School
Awards	2018 - Nanjing University 'My Favorite Teacher' 2019 - Nanjing University 'Charismatic Mentor'

University/Lab Affiliation and Title

Nanjing University

Faculty

Medical School

Academic Background & Achievements

1993 - Graduated from Huazhong University of Science and Technology, Clinical Medicine (German class)
2001 - Master's in Pathology from Jinan University Medical School
2003 - PhD from Ulm University Medical School, Germany
2006 - Postdoctoral Researcher at Ulm University Medical School, Germany
2009 - Postdoctoral Researcher at Munich University Medical School, Germany
Published research in top journals like Cancer Cell, Cancer Res., Int J Cancer, JVI, Nature Comm., Mol Ther., and BJC
Granted 3 invention patents and applied for 10 national invention patents
Led 4 national and 2 provincial research projects

Work Experience

1993-2001 - Attending Physician, Neurosurgery, Third Affiliated Hospital of Jinan University Medical School
2001-2003 - PhD Student, Ulm University Medical School, Germany
2003-2006 - Postdoctoral Researcher, Ulm University Medical School, Germany
2007-2009 - Postdoctoral Researcher, Munich University Medical School, Germany
2009-present - Professor and Doctoral Supervisor, Nanjing University Medical School

Awards

2018 - Nanjing University 'My Favorite Teacher'
2019 - Nanjing University 'Charismatic Mentor'

Areas of Focus	Recombinant oncolytic virus-mediated oncolytic immunotherapy Biotherapy regulating tumor inflammation and metabolic microenvironment
Publications	Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma, Zuo S, Wei M, Wang S, Dong J, Wei J, 2020 Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma, Meng G, Li B, Chen A, Zheng M, Xu T, Zhang H, Dong J, Wu J, Yu D, Wei J, 2020 Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy, Xia M, Luo D, Dong J, Zheng M, Meng G, Wu J, Wei J, 2019 Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC, Zhang Y, Zhang H, Wei M, Mou T, Shi T, Ma Y, Cai X, Li Y, Dong J, Wei J, 2019 A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer, Zuo S, Wei M, Zhang H, Chen A, Wu J, Wei J, Dong J, 2019 Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma, Meng G, Fei Z, Fang M, Li B, Chen A, Xu C, Xia M, Yu D, Wei J, 2019 CD8+ T cells mediate the antitumor activity of frankincense and myrrh in hepatocellular carcinoma, Xu C, Lu X, Liu W, Chen A, Meng G, Zhang H, Li B, Zhang Y, Wu J, Wei J, 2018 Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading, Xu C, Xia M, Meng G, Li C, Jiang A, Wei J, 2018 The anti-inflammatory NHE-06 restores antitumor immunity by targeting NF-κB/IL-6/STAT3 signaling in hepatocellular carcinoma, Lu X, Wo G, Li B, Xu C, Wu J, Jiang C, Wei J NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression, Ju J, Chen A, Deng Y, Liu M, Wang Y, Wang Y, Nie M, Wang C, Ding H, Yao B, Gui T, Li X, Xu Z, Ma C, Song Y, Kvansakul M, Zen K, Zhang CY, Luo C, Fang M, Huang DCS, Allis CD, Tan R, Zeng CK, Wei J, Zhao Q, 2017 Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment, Chen A, Zhang Y, Meng G, Jiang D, Zhang H, Zheng M, Xia M, Jiang A, Wu J, Beltinger C, Wei J, 2017

Areas of Focus

Recombinant oncolytic virus-mediated oncolytic immunotherapy
Biotherapy regulating tumor inflammation and metabolic microenvironment

Publications

Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma, Zuo S, Wei M, Wang S, Dong J, Wei J, 2020
Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma, Meng G, Li B, Chen A, Zheng M, Xu T, Zhang H, Dong J, Wu J, Yu D, Wei J, 2020
Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy, Xia M, Luo D, Dong J, Zheng M, Meng G, Wu J, Wei J, 2019
Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC, Zhang Y, Zhang H, Wei M, Mou T, Shi T, Ma Y, Cai X, Li Y, Dong J, Wei J, 2019
A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer, Zuo S, Wei M, Zhang H, Chen A, Wu J, Wei J, Dong J, 2019
Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma, Meng G, Fei Z, Fang M, Li B, Chen A, Xu C, Xia M, Yu D, Wei J, 2019
CD8+ T cells mediate the antitumor activity of frankincense and myrrh in hepatocellular carcinoma, Xu C, Lu X, Liu W, Chen A, Meng G, Zhang H, Li B, Zhang Y, Wu J, Wei J, 2018
Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading, Xu C, Xia M, Meng G, Li C, Jiang A, Wei J, 2018
The anti-inflammatory NHE-06 restores antitumor immunity by targeting NF-κB/IL-6/STAT3 signaling in hepatocellular carcinoma, Lu X, Wo G, Li B, Xu C, Wu J, Jiang C, Wei J
NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression, Ju J, Chen A, Deng Y, Liu M, Wang Y, Wang Y, Nie M, Wang C, Ding H, Yao B, Gui T, Li X, Xu Z, Ma C, Song Y, Kvansakul M, Zen K, Zhang CY, Luo C, Fang M, Huang DCS, Allis CD, Tan R, Zeng CK, Wei J, Zhao Q, 2017
Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment, Chen A, Zhang Y, Meng G, Jiang D, Zhang H, Zheng M, Xia M, Jiang A, Wu J, Beltinger C, Wei J, 2017

Oncolytic Virus Immunotherapy Recombinant Virus Tumor Inflammation Metabolic Microenvironment Biotherapy Cancer Treatment Adenovirus Poxvirus Rna Therapy

De-Cai Yu - Nanjing University

Xu Yang - Southern University of Science and Technology

Hua-Wen Sun - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us